Brain cancer breakthrough: Experimental vaccine trains immune system to target remaining tumor cells after surgery

November 14, 2012 by John Murray, University of California, Irvine
Brain cancer breakthrough
“Cancer cells are like crabgrass: Once they take root, they’re hard to eradicate,” says UC Irvine neuro-oncologist Dr. Daniela Bota, who’s exploring the use of immunotherapy against glioblastoma multiforme. Credit: Paul R. Kennedy

UC Irvine oncologists are looking for new ways to treat glioblastoma multiforme, the deadliest type of brain cancer. While surgery followed by chemotherapy and radiation is the current standard of care, it doesn't fully eliminate the cancer. The goal is to develop an additional therapy that seeks out and destroys the cancer cells that inevitably remain.

Dr. Daniela Bota is testing whether enlisting the immune system to fight the tumor can complement surgery, drugs and radiation and improve a patient's odds of surviving. Nearly 14,000 Americans are diagnosed each year with glioblastoma multiforme, and only 10 percent will survive more than five years, according to the .

" are like crabgrass: Once they take root, they're hard to eradicate," says Bota, a neuro- and medical director of UC Irvine's Comprehensive Brain Tumor Program. "The immune system is powerful, but it must be trained to recognize these cancer cells before it can do its job."

Enter the experimental glioblastoma vaccine. Think of it as a personal smoothie: Pulverized pieces of a patient's surgically excised tumor are blended in a laboratory with his or her own . When injected back into the body, the concoction programs the individual's immune system with new targets – any remaining cancer cells.

"The lab becomes like a training camp outside the body," Bota says.

She and Dr. Jose Carrillo plan to test several experimental immunotherapies and are now enrolling patients at UC Irvine's Chao Family Comprehensive Cancer Center in a trial of a dendritic cell vaccine. are a type of white blood cells that, once trained, can paint bull's-eyes on cancer cells. A previous trial demonstrated that this vaccine is safe and, in some cases, doubled patients' median survival after diagnosis from 15 months to about 31 months.

"The current standard of care prolongs survival, but it does not fully destroy the cancer," Bota says. She believes the vaccine can help get rid of remaining tumor cells and further extend patients' lives.

A glioblastoma vaccine does not eliminate the need for brain surgery, which is also required to collect the cancer cells used in the "smoothie."

"We try to be aggressive and remove as much tumor as possible," says Dr. Johnny Delashaw, chair of UC Irvine's Department of Neurological Surgery and surgical director of the brain tumor program. "If we can get more than 90 percent, the patient has a much greater chance of surviving."

Other vaccines under development for glioblastoma also enlist the immune system.

One identifies and targets a surface protein, EGFRvIII, that regulates cell growth. Another, based on the knowledge that cancer cells mutate, includes a combination of different glioblastoma tumor cells.

"Everyone responds differently, but immunotherapy has a great chance to be the next leap forward in cancer treatment," Bota says.

Explore further: UC Irvine opens clinical trial of novel treatment for brain cancer

Related Stories

UC Irvine opens clinical trial of novel treatment for brain cancer

October 10, 2012
UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

Researchers study vaccine as potential weapon against aggressive brain tumors

July 24, 2012
Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor. The trial is studying the vaccine's effect ...

Lifting the fog: Finding by neuro-oncologist could help eliminate 'chemo brain'

September 29, 2011
After receiving her medical degree in her homeland of Romania, Dr. Daniela Bota came to the U.S. to earn a doctorate in molecular biology to better understand why people develop neurodegenerative diseases such as Alzheimer's.

Novel brain tumor vaccine acts like bloodhound to locate cancer cells

January 5, 2012
A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.